Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease, as well as to treat chronic kidney disease-associated with pruritus. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation; and Rutgers to develop and commercialize products incorporating nalbuphine for any human or animal use. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
IPO Year: 2019
Exchange: NASDAQ
Website: trevitherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/13/2025 | $13.00 | Outperform | Leerink Partners |
| 8/21/2025 | $18.00 | Overweight | Morgan Stanley |
| 7/1/2025 | $25.00 | Overweight | Cantor Fitzgerald |
| 5/28/2025 | $21.00 | Buy | H.C. Wainwright |
| 3/10/2025 | $9.00 → $29.00 | Outperform → Strong Buy | Raymond James |
| 3/10/2025 | $8.00 → $25.00 | Buy | Needham |
| 12/12/2024 | $6.00 → $7.50 | Buy | H.C. Wainwright |
| 9/9/2024 | $6.00 → $7.00 | Outperform | Leerink Partners |
| 8/30/2024 | $6.00 | Buy | H.C. Wainwright |
| 8/30/2024 | $9.00 | Outperform | Raymond James |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
Fastest customizable press release news feed in the world
Completed follow-on common stock offering with net proceeds of ~$162 million, extending expected cash runway into 2030 through potential FDA approval of Haduvio in IPF-related chronic cough and continued pipeline advancement Clinical development plans remain on track across all chronic cough indications Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung
Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral presentation, including key subgroup analyses by baseline cough count and background anti-fibrotic use An exploratory post-hoc analysis of the effects of nalbuphine ER and placebo on cough bouts from the Phase 2b CORAL trial in patients with IPF-related chronic cough and the Phase 2a RIVER trial in patients with refractory chronic cough Drug–drug interaction data from a Phase 1 study evaluating pharmacokinetics and safety following co-administration of nalbuphine ER with pirfenidone or nintedanib NEW HAVEN, Conn., April 30, 2026 (GLO
NEW HAVEN, Conn., April 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, May 5, 2026, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended March 31, 2026. Conference Call and WebcastTo register for the live conference call and we
NEW HAVEN, Conn., April 23, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will participate in several upcoming events in May. Trevi Therapeutics Investor and Analyst DayMay 7, 2026, Midtown New York, New York10:00 a.m. to 12:00 p.m. ET, followed by lunch and open discussionsRepresentatives: Trevi senior management will be joined by key opinion leaders
NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the closing of its previously announced underwritten public offering of 13,340,000 shares of its common stock at a public offering price of $13.00 per share, which includes 1,740,000 additional shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of
NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the pricing of its previously announced underwritten public offering of 11,600,000 shares of its common stock at a public offering price of $13.00 per share, for total proceeds of approximately $150 million, before deducting underwriting discounts and commissions and expenses payable by Trevi. All of t
NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. All of the shares in the offering are being offered by Trevi. In addition, Trevi expects to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of the shares of its common
NEW HAVEN, Conn., April 01, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following events. 25th Annual Needham Virtual Healthcare ConferenceApril 13 – 16, 2026, Virtual Fireside Chat: April 13, 12:45 p.m. ET Trevi Representatives: Jennifer Good, President and CEO, and David Hastings, CFORaymond James 2026 Biotech Innovatio
Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track to initiate a Phase 2b clinical trial for the treatment of patients with refractory chronic cough in the second quarter of 2026 Company ended 2025 with $188.3 million in cash, cash equivalents and marketable securities, with expected cash runway into 2028 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., March 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investig
NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, March 17, 2026, at 4:30 p.m. ET, to provide business updates and review the Company's financial results for the fourth quarter and year ended December 31, 2025. Conference Call and WebcastTo register for the live co
8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
SCHEDULE 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
10-Q - Trevi Therapeutics, Inc. (0001563880) (Filer)
8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
DEF 14A - Trevi Therapeutics, Inc. (0001563880) (Filer)
DEFA14A - Trevi Therapeutics, Inc. (0001563880) (Filer)
424B5 - Trevi Therapeutics, Inc. (0001563880) (Filer)
8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
424B5 - Trevi Therapeutics, Inc. (0001563880) (Filer)
PRE 14A - Trevi Therapeutics, Inc. (0001563880) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Leerink Partners initiated coverage of Trevi Therapeutics with a rating of Outperform and set a new price target of $13.00
Morgan Stanley initiated coverage of Trevi Therapeutics with a rating of Overweight and set a new price target of $18.00
Cantor Fitzgerald initiated coverage of Trevi Therapeutics with a rating of Overweight and set a new price target of $25.00
H.C. Wainwright initiated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $21.00
Raymond James upgraded Trevi Therapeutics from Outperform to Strong Buy and set a new price target of $29.00 from $9.00 previously
Needham reiterated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $25.00 from $8.00 previously
H.C. Wainwright reiterated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $7.50 from $6.00 previously
Leerink Partners resumed coverage of Trevi Therapeutics with a rating of Outperform and set a new price target of $7.00 from $6.00 previously
H.C. Wainwright initiated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $6.00
Raymond James initiated coverage of Trevi Therapeutics with a rating of Outperform and set a new price target of $9.00
Live Leadership Updates
Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that David Hastings will assume the role of Chief Financial Officer effective January 6, 2026. www.trevitherapeutics.com (PRNewsfoto/Trevi
WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie
NEW HAVEN, Conn., Sept. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of James V. Cassella, Ph.D., as Chief Development Officer (CDO). www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)" alt="Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)"> "I am delighte
Margaret Garin, MD, MSCR, joins team to advance the development of Haduvio in chronic cough indications NEW HAVEN, Conn., April 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of Margaret Garin, MD, MSCR, as Vice President of Clinical Development. Dr. Garin will be responsible for progressing the clinical development of Haduvio in chronic cough and brings unique and relevant experience from her previous lead role in clinical d
David Clark, MD, MRCP, will lead the continued development of Haduvio™ NEW HAVEN, Conn., Nov. 14, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced the appointment of David Clark, MD, MRCP, as Chief Medical Officer (CMO). Dr. Clark will join Trevi's executive team and be responsible for the strategy and execution of Haduvio's clinical programs.
NEW HAVEN, Conn., Aug. 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced the appointment of Lisa Delfini, CPA, as Chief Financial Officer and Danine Summers, as Vice President, Medical Affairs. Ms. Delfini will lead the accounting and finance operations. Ms. Summers will be responsible for educating the medical community on Haduvio's data and development programs through publications, congresses and relationship building with key opinion leaders.
Industry Veteran to Lead the Clinical Development of Haduvio™ in Multiple Indications NEW HAVEN, Conn., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced the appointment of William Forbes, Pharm.D., as Chief Development Officer. Dr. Forbes will join Trevi’s senior management team and be responsible for leading the clinical development of Haduvio which is in late-stage clinical trials in its two lead indications. “I am happy to welcome Bill to our executive leadership team,” sai
Live finance-specific insights
NEW HAVEN, Conn., April 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, May 5, 2026, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended March 31, 2026. Conference Call and WebcastTo register for the live conference call and we
Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track to initiate a Phase 2b clinical trial for the treatment of patients with refractory chronic cough in the second quarter of 2026 Company ended 2025 with $188.3 million in cash, cash equivalents and marketable securities, with expected cash runway into 2028 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., March 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investig
NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, March 17, 2026, at 4:30 p.m. ET, to provide business updates and review the Company's financial results for the fourth quarter and year ended December 31, 2025. Conference Call and WebcastTo register for the live co
Company preparing to initiate comprehensive Phase 3 program for chronic cough in patients with idiopathic pulmonary fibrosis in first half of 2026 Company ended the third quarter of 2025 with $194.9 million in cash, cash equivalents and marketable securities with expected cash runway into 2028 Management to host a conference call and webcast today at 4:30 p.m. EST NEW HAVEN, Conn., Nov. 13, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF I
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., Nov. 6, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Thursday, November 13, 2025, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended September 30, 2025.
Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF Closed $115 million underwritten offering with expected cash runway into 2029 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., Aug. 7, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced financial results for the
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., July 31, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Thursday, August 7, 2025, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended June 30, 2025.
Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p<0.0001; 27 mg BID p<0.01); a -43.3% placebo-adjusted change from Baseline was achieved at the 108 mg BID dose group Patients saw a rapid reduction in 24-hour cough frequency at Week 2, the first time point measured Haduvio was generally well-tolerated at all doses; discontinuation rates due to adverse events were similar in the Haduvio and placebo groups, 5.6% and 5.0%, respectively Trevi plans to request an End-of-Phase 2 meeting with the FDA later this year and is planning to initiate the Phase 3 program in the first half of 2026 Company to hos
Conference call and webcast to be held at 8:30 a.m. ET NEW HAVEN, Conn., June 1, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced a conference call and live webcast taking place tomorrow, Monday, June 2nd, 2025, at 8:30 a.m. ET, to share topline results from the Phase 2b CORAL trial of Haduvio in patients with IPF chronic cough. www.trevitherapeuti
Completed enrollment and last patient last visit in the Phase 2b CORAL trial in IPF patients with chronic cough; topline results continue to be expected in the second quarter of 2025 Announced positive topline results from the Phase 2a RIVER trial in patients with refractory chronic cough Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., May 8, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC)
This live feed shows all institutional transactions in real time.
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13D/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13D/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)